Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Amarex Clinical Research
ICON Laboratories
ARANZ Medical
Information provided by (Responsible Party):
Macrocure Ltd.
ClinicalTrials.gov Identifier:
NCT01421966
First received: August 21, 2011
Last updated: November 4, 2014
Last verified: November 2014

August 21, 2011
November 4, 2014
August 2011
June 2015   (final data collection date for primary outcome measure)
Proportion of patients with complete healing/closure of their target ulcer at any time during the 16-week double-blind core treatment period with sustained complete closure for 4 additional weeks of follow-up. [ Time Frame: up to 20 weeks ] [ Designated as safety issue: No ]
Proportion of patients with complete healing/closure of their target ulcer at any time during the 16-week double-blind core treatment period with sustained complete closure for 4 additional weeks of follow-up [ Time Frame: up to 20 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01421966 on ClinicalTrials.gov Archive Site
  • Time to complete closure of the Target Ulcer during the core double blind treatment phase with sustained complete closure for 4 additional weeks of follow-up. [ Time Frame: up to 20 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients with at least 50% closure of target ulcer during the 16-week core treatment period. [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients whose Target Ulcer completely closed during the core double blind treatment phase and remained closed at the FU12 follow-up visit. [ Time Frame: up to 28 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients (and individual treated ulcers) with all ulcers completely healed/closed at any time during the 16-week double-blind core treatment period with sustained complete closure for 4 additional weeks of follow-up. [ Time Frame: up to 20 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients (and individual treated ulcers) with at least 50% closure of target ulcer (and individual treated ulcers) during the16-week core treatment period. [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Time to complete closure/healing of all ulcers (and individual treated ulcers) during the 16-week core treatment period with sustained complete closure for 4 additional weeks of follow-up [ Time Frame: up to 20 weeks ] [ Designated as safety issue: No ]
  • Time to complete closure/healing of the target ulcer during the 16-week core treatment period with sustained complete closure for 4 additional weeks of follow-up. [ Time Frame: up to 20 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients whose target ulcer (and individual treated ulcers) completely closed/healed during the 16-week core treatment period and remained closed at the Week 12 follow-up visit. [ Time Frame: up to 28 weeks ] [ Designated as safety issue: No ]
  • Proportion of patients whose target ulcer (and individual treated ulcers) had ulcer recurrence following complete closure during the 16-week core treatment period and during the 12-week follow-up period [ Time Frame: up to 28 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes
A Phase III Multicenter, Randomized, Double-Blind, Parallel-Group, Sham-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Wound Care in Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus

Chronic foot ulcers are particularly prevalent in patients with underlying diabetes mellitus. These ulcers are reported to be the leading cause of hospitalization among people with diabetes.

The purpose of this study is to evaluate CureXcell® in treating chronic lower extremity ulcers in adults with diabetes mellitus. CureXcell® is a cell based therapy, containing activated homologous white blood cells prepared from donated healthy whole blood. A total of 280 patients will be randomized to receive either CureXcell® or sham.

Chronic foot ulcers are particularly prevalent in patients with underlying diabetes mellitus. The prevalence of diabetes mellitus is growing at epidemic rates in Europe, United States and in general worldwide. Foot ulceration is a serious complication of diabetes mellitus associated with increased risk of infection, gangrene and amputation. These ulcers are reported to be the leading cause of hospitalization among people with diabetes. Despite existing ulcer therapies and technologies, there continues to be a great necessity for new wound healing technologies that will further improve healing rates for these chronic ulcers that remain a major source of morbidity, concern, and cost. This Phase 3 multinational, multicenter, randomized, double-blind, controlled study is designed to evaluate CureXcell® in treating lower extremity chronic ulcers in adults with Diabetes Mellitus.

CureXcell® is a cell based therapy obtained from donated whole blood. The blood are collected from healthy, young adult (age 18-40), the cells separated and then activated by hypo-osmotic shock.

A total of 280 patients, in approximately 35 sites in the US, Canada and Israel, will be randomized to receive either CureXcell® or control.

The primary objective of the study is to evaluate the clinical benefit of CureXcell® (study biologic) compared to control, as adjunct to Good Ulcer Care. Additional objectives are to demonstrate safety, tolerability and durability of CureXcell® compared to control.

The study has two phases: a core double-blind phase and a follow up phase.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Lower Extremity Chronic Ulcers in Diabetics
  • Biological: CureXcell®
    CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.
  • Biological: Sham injection
    The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
  • Experimental: CureXcell®
    Intervention: Biological: CureXcell®
  • Sham Comparator: Sham injection
    Intervention: Biological: Sham injection
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
280
August 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Males or females at least 18 years of age with diabetes type 1 or type 2;
  2. Patients with HbA1c ≤ 12%;
  3. Patients with at least one lower extremity (on or below the malleolus (ankle bone)), at least full-thickness ulcer (penetrating through the whole layer of the skin), which has been unresponsive to any treatment for at least 4 weeks;
  4. Ulcers with an area between ≥ 1 cm2 and ≤ 20 cm2 (after sharp debridement of free, non-viable, hyperkeratotic and fibrotic tissue to the extent possible);
  5. Ankle Brachial Index ≥ 0.65;

Exclusion Criteria:

  1. Patients with more than two ulcers on the same foot or more than a total of three chronic ulcers;
  2. Patients with ulcers primarily caused by venous insufficiency;
  3. Patients whose target ulcer has decreased > 25% in size from screening to baseline;
  4. Malignancy within the past 5 years excluding successfully treated basal cell carcinoma;
  5. Significantly compromised immunity for any reason including radiation therapy, chemotherapy or HIV;
  6. Current clinical osteomyelitis;
  7. Acute Charcot foot;
  8. Current sepsis;
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada,   Israel
 
NCT01421966
MC-102
Yes
Macrocure Ltd.
Macrocure Ltd.
  • Amarex Clinical Research
  • ICON Laboratories
  • ARANZ Medical
Principal Investigator: Vickie Driver, MS, DPM, FACFAS VA New England Health Care Division
Macrocure Ltd.
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP